- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Vosaroxin Fails in Phase 3 AML Trials in the Elderly
Sunesis Pharmaceuticals announced the failure of a phase 3 study Monday morning. The company's experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.
(SNSS)
Sunesis Pharmaceuticals announced the failure of a phase 3 study Monday morning. The company's experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.
In the phase 3 study of 711 elderly AML patients, treatment with vosaroxin reduced the risk of death by only 13% compared to a placebo. The survival trend was not statistically significant, failing the primary endpoint of the study. At the median, vosaroxin patients lived 7.5 months compared to 6.1 months for placebo patients.
Sunesis performed another analysis of the study excluding AML patients who later underwent a stem cell transplant. In this subgroup analysis, vosaroxin reduced the risk of death by 19% compared to placebo, which was statistically significant. At the median, the survival benefit was 6.7 months for vosaroxin patients compared to 5.3 months for placebo patients.
Link to the news on The Street: http://bit.ly/1nWShlF
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
